Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Pharmacovigilance of antimalarial treatment in Africa: is it possible?

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Talisuna, A. O. en_US
dc.contributor.author Staedke, S. G. en_US
dc.contributor.author D'Alessandro, U. en_US
dc.date.accessioned 2007-12-06T14:34:13Z
dc.date.available 2007-12-06T14:34:13Z
dc.date.issued 2006 en_US
dc.identifier.doi http://dx.doi.org/10.1186/1475-2875-5-50
dc.identifier.other ITG-P1B en_US
dc.identifier.other ITG-PLA en_US
dc.identifier.other PARAS en_US
dc.identifier.other U-MALAR en_US
dc.identifier.other JIF en_US
dc.identifier.other DOI en_US
dc.identifier.other URL en_US
dc.identifier.other FTA en_US
dc.identifier.other ELECTRONIC en_US
dc.identifier.other ABSTRACT en_US
dc.identifier.uri http://hdl.handle.net/10390/292
dc.description.abstract Pharmacovigilance, defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug related problem", is increasingly being recognized in Africa. Many African countries have simultaneously adopted artemisinin derivative based combination therapy (ACT) as first-line treatment for uncomplicated malaria, offering an opportunity to assess the safety of these drugs when used widely. While ACTs appear to be safe and well-tolerated, there is little experience with these medicines in Africa, outside clinical trials. Pharmacovigilance for ACTs and other combination treatments in Africa is essential. Malaria transmission intensity is high and antimalarial medicines are used frequently. Presumptive treatment of fever with antimalarials is common, often in the absence of a confirmed diagnosis, using drugs obtained without a prescription. Informal use of antimalarial drugs may increase the risk of incorrect dosing, inappropriate treatment, and drug interactions, which may impact negatively on drug safety. Furthermore, the administration of antimalarial treatments in patients with a concomitant illness, including HIV/AIDs, tuberculosis and malnutrition, is a concern. African countries are being encouraged to establish pharmacovigilance systems as ACTs are rolled out. However, pharmacovigilance is difficult, even in countries with a well-developed health care system. The rationale for pharmacovigilance of antimalarial drugs is discussed here, outlining the practical challenges and proposing approaches that could be adopted in Africa. en_US
dc.language English en_US
dc.publisher BioMed Central en_US
dc.subject Protozoal diseases en_US
dc.subject Malaria en_US
dc.subject Drug therapy en_US
dc.subject Artemisinin combination therapies (ACT) en_US
dc.subject Rational drug use en_US
dc.subject Safety en_US
dc.subject Adverse effects en_US
dc.subject Concomitant infections en_US
dc.subject Surveillance system en_US
dc.subject Africa en_US
dc.title Pharmacovigilance of antimalarial treatment in Africa: is it possible? en_US
dc.type Article-E en_US
dc.citation.issue 50 en_US
dc.citation.jtitle Malaria Journal en_US
dc.citation.volume 5 en_US
dc.citation.pages 8 en_US
dc.publisher.place London en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/16780575
dc.identifier.url http://www.malariajournal.com/content/5/1/50
dc.citation.jabbreviation Malaria J en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record